Call to arrange a consultation
+1 416 777 0888

Janssen Inc. v. Celltrion Healthcare Co. et al.

Represented Celltrion Healthcare Co., Ltd. in an application commenced by Janssen pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations in relation to the drug infliximab.  Celltrion's success in the application is reported at 2016 FC 525, affirmed at 2016 FC 651.

Meet the team